Table 1.
Demographic and baseline characteristics (safety analysis set)
| Parameters | Placebo N=1,021 n (%) |
Galantamine N=1,024 n (%) |
|---|---|---|
| Sex | ||
| Women | 654 (64.1%) | 671 (65.5%) |
| Men | 367 (35.9%) | 353 (34.5%) |
| Race | ||
| White | 1,018 (99.7%) | 1,024 (100.0%) |
| Multiple | 1 (0.1%) | 0 |
| Other | 2 (0.2%) | 0 |
| Age (years) | ||
| Mean (SD) | 73 (8.7) | 73 (8.9) |
| <61 years | 112 (11.0%) | 112 (10.9%) |
| 61 to <76 years | 467 (45.7%) | 466 (45.5%) |
| ≥76 years | 442 (43.3%) | 446 (43.6%) |
| Mean (SD) age at time of probable AD diagnosis | 72 (8.78) | 71.9 (8.92) |
| Mean (SD) age at onset of cognitive problem | 69.7 (8.96) | 69.6 (9.17) |
| Mean (SD) years since diagnosis of cognitive problems | 3.0 (2.69) | 2.9 (2.69) |
| Mean (SD) years since probable diagnosis of Alzheimer-type dementia | 0.8 (1.64) | 0.8 (1.45) |
| Smoker | ||
| Currently | 54 (5.3%) | 55 (5.4%) |
| In the past | 183 (17.9%) | 166 (16.2%) |
| Weight (kg), mean (SD) | 70 (12.94) | 70 (12.84) |
| MMSE score | ||
| Mean (SD) | 19.0 (4.04) | 19.0 (4.12) |
| <18 group | 378 (37.0%) | 361 (35.3%) |
| ≥18 group | 643 (63.0%) | 663 (64.7%) |
| DAD score, mean (SD) | 60.9 (21.09) | 61.8 (21.61) |
Abbreviations: AD, Alzheimer’s disease; DAD, Disability Assessment in Dementia; MMSE, Mini-Mental State Examination; SD, standard deviation.